[Adjuvant GM-CSF cytokine gene therapy for breast cancer].
The aim of this study was to examine the enhancement of antitumor immunity of irradiated granulocyte macrophage-colony-stimulating factor (GM-CSF) gene-transduced mouse breast cancer cells.


METHODS
BALBMC mouse were vaccinated subcutaneously with saline or irradiated mouse breast cancer cells, BALBMC (1 x 10(6)/mouse), infected or not infected with recombinant adenovirus harboring GM-CSF gene on day-7. Mice were injected with parental cells (1 x 10(5)/mouse) on day 0.


RESULTS
No mice vaccinated with irradiated GM-CSF producing BALBMC cells developed a tumor during the observation period of up to 16 weeks, whereas 100% of mice injected with saline developed a tumor.


CONCLUSIONS
Our study demonstrates the feasibility of this immunotherapeutic approach as a novel adjuvant cancer therapy after surgery for breast cancer.
Ogawa
T
T
Dept. of Surgery, Shimonoseki City Hospital.
Kusumoto
M
M
Kuroki
S
S
Nagata
S
S
Yamanaka
N
N
Kawano
R
R
Yoshida
J
J
Shinohara
M
M
Matsuo
K
K
D000818:Animals; D001943:Breast Neoplasms / Q000276:immunology / Q000517:prevention & control*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D016207:Cytokines; D005260:Female; D015316:Genetic Therapy; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000235:genetics*; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D008807:Mice, Inbred BALB C
D019496:Cancer Vaccines; D016207:Cytokines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor